top of page
Science Woman_Dark Red-01.png

PIPELINE

The future standard of care in
acute pain management

Mission Vision

Advancing loco-regional anesthesia

Rebel Medicine’s R&D pipeline is designed to address important unmet medical needs in acute and post-operative pain management. New product candidates are based on our proprietary drug delivery technologies.

Small icon.png

R&D PIPELINE

Products in development

Discovery

Preclinical

IND/IDE-enabling

Clinical

Registration

Alevatrix™

Postoperative pain

ALX-UL

Postoperative pain

RBL-001

Acute & postoperative pain

Alevaderm™

Painful dermal injury

Alevatrix™

Extended-release bupivacaine gel

Alevatrix™ is an injectable long-acting formulation of the local anesthetic, bupivacaine, under development to enable opioid-free management of postoperative pain. The product is based on Rebel Medicine’s proprietary injectable gel technology and will be packaged in a ready-to-use, prefilled syringe that can be used in both regional anesthesia via nerve blocks and local anesthesia via instillation. 

Opioid-based medications are a mainstay of postoperative pain management today with approximately 80% of surgical patients receiving opioid prescriptions after surgery. However, their use is associated with a variety of adverse events, prolonged hospital length of stay and increased costs of care. The pain after surgery is most intense in the first 72 hours, after which non-opioid systemic medications such as acetaminophen and NSAIDs are sufficient for most patients. Alevatrix™ has demonstrated in large animal models that it can control pain locally through the first 72-96 hours. By minimizing or eliminating the need for opioids after surgery, Alevatrix™ has the potential to reduce the cost and improve outcomes for patients undergoing surgery.

bottom of page